KR20240157067A - 미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도 - Google Patents
미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도 Download PDFInfo
- Publication number
- KR20240157067A KR20240157067A KR1020247032615A KR20247032615A KR20240157067A KR 20240157067 A KR20240157067 A KR 20240157067A KR 1020247032615 A KR1020247032615 A KR 1020247032615A KR 20247032615 A KR20247032615 A KR 20247032615A KR 20240157067 A KR20240157067 A KR 20240157067A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- present disclosure
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315438P | 2022-03-01 | 2022-03-01 | |
| US63/315,438 | 2022-03-01 | ||
| US202363439477P | 2023-01-17 | 2023-01-17 | |
| US63/439,477 | 2023-01-17 | ||
| PCT/US2023/014275 WO2023167925A1 (en) | 2022-03-01 | 2023-03-01 | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240157067A true KR20240157067A (ko) | 2024-10-31 |
Family
ID=85772026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247032615A Pending KR20240157067A (ko) | 2022-03-01 | 2023-03-01 | 미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20250236629A1 (https=) |
| EP (1) | EP4486748A1 (https=) |
| JP (1) | JP2025507852A (https=) |
| KR (1) | KR20240157067A (https=) |
| CN (1) | CN119110802A (https=) |
| AU (1) | AU2023228830A1 (https=) |
| CA (1) | CA3245204A1 (https=) |
| CL (1) | CL2024002576A1 (https=) |
| IL (1) | IL315237A (https=) |
| MX (1) | MX2024010608A (https=) |
| TW (1) | TW202400606A (https=) |
| WO (1) | WO2023167925A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| KR20250155550A (ko) | 2023-03-16 | 2025-10-30 | 다케다 야쿠힌 고교 가부시키가이샤 | 매크로시클릭 헤테로시클 화합물 및 이의 용도 |
| US20240425521A1 (en) | 2023-06-01 | 2024-12-26 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| SG11202106791XA (en) | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| FI4065585T3 (fi) * | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| WO2022051583A1 (en) * | 2020-09-03 | 2022-03-10 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists |
-
2023
- 2023-03-01 KR KR1020247032615A patent/KR20240157067A/ko active Pending
- 2023-03-01 IL IL315237A patent/IL315237A/en unknown
- 2023-03-01 WO PCT/US2023/014275 patent/WO2023167925A1/en not_active Ceased
- 2023-03-01 EP EP23713207.1A patent/EP4486748A1/en active Pending
- 2023-03-01 CN CN202380037293.8A patent/CN119110802A/zh active Pending
- 2023-03-01 TW TW112107384A patent/TW202400606A/zh unknown
- 2023-03-01 JP JP2024551975A patent/JP2025507852A/ja active Pending
- 2023-03-01 MX MX2024010608A patent/MX2024010608A/es unknown
- 2023-03-01 CA CA3245204A patent/CA3245204A1/en active Pending
- 2023-03-01 AU AU2023228830A patent/AU2023228830A1/en active Pending
-
2024
- 2024-08-28 US US18/817,943 patent/US20250236629A1/en active Pending
- 2024-08-29 CL CL2024002576A patent/CL2024002576A1/es unknown
-
2025
- 2025-04-11 US US19/177,396 patent/US20250289828A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119110802A (zh) | 2024-12-10 |
| US20250289828A1 (en) | 2025-09-18 |
| CL2024002576A1 (es) | 2025-01-10 |
| TW202400606A (zh) | 2024-01-01 |
| US20250236629A1 (en) | 2025-07-24 |
| JP2025507852A (ja) | 2025-03-21 |
| IL315237A (en) | 2024-10-01 |
| EP4486748A1 (en) | 2025-01-08 |
| WO2023167925A1 (en) | 2023-09-07 |
| CA3245204A1 (en) | 2023-09-07 |
| MX2024010608A (es) | 2024-09-23 |
| AU2023228830A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12503475B2 (en) | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | |
| JP7811578B2 (ja) | 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 | |
| KR20240157067A (ko) | 미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도 | |
| JP7443625B2 (ja) | ビシクロヘプタンピロリジンオレキシン受容体アゴニスト | |
| IL275058B1 (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| EP3891157A1 (en) | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | |
| WO2025072451A1 (en) | Ras-pi3k inhibitors for the treatment of cancer and immunological diseases | |
| CN119156375A (zh) | 双环杂环衍生物和相关用途 | |
| JP2024516633A (ja) | オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物 | |
| WO2022207935A1 (en) | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists | |
| TW202309051A (zh) | 食慾素受體促效劑及其用途 | |
| JP2024520395A (ja) | 置換される縮合二環式大環状化合物および関連のある治療方法 | |
| TW202417432A (zh) | 抗菌化合物 | |
| JP2025516719A (ja) | Ｎｌｒｐ３を阻害するためのオキソインドリニルアミド誘導体およびその使用 | |
| WO2022147302A1 (en) | 4-phenyl-indole derivatives and related uses | |
| EP3983388A1 (en) | Sulfonamide derivatives and uses thereof | |
| EA052303B1 (ru) | Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения | |
| TW202530205A (zh) | 經取代之芳基磺醯胺及其組合物及用途 | |
| WO2025106644A1 (en) | Heterocyclic compounds as inhibitors of alpha-v beta-1 integrin | |
| CA3260373A1 (en) | MACROCYCLICAL BCL6 DEGRADING AGENTS | |
| TW202604484A (zh) | 經取代之芳基磺醯胺及其組合物及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |